Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Questions raised about the future of lung cancer vaccination?

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

EORTC and the management of clinical trial data

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Molecular targeting in cancer and the impact on personalised medicine

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer